Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Nov 2022
01 Nov 2022
Historique:
pubmed:
20
9
2022
medline:
15
10
2022
entrez:
19
9
2022
Statut:
ppublish
Résumé
The platinum-based antineoplastic drug cisplatin is commonly used for chemotherapy in clinics. This work aims to demonstrate a radio-platinum tracer is useful for precisely quantifying small amounts of platinum in pharmacokinetics studies. A cisplatin radiotracer (radio-cisplatin) was synthesized, and a comprehensive evaluation of cisplatin over 7 days after its intravenous injection into nude mice bearing a subcutaneous lung tumor (H460) was conducted. A biphasic retention curve in the whole body and blood was observed [ T1/2 (α) = 1.14 h, T1/2 (β) = 5.33 days for the whole body, and T1/2 (α) = 23.9 min, T1/2 (β) = 4.72 days for blood]. The blood concentration decreased within 1 day after injection. Most of the intact cisplatin was excreted via the kidneys in the early time points, and a small part was distributed in tissues including tumors. The plasma protein binding rate of cisplatin increased rapidly after injection, and the protein-bound cisplatin remained in the blood longer than intact cisplatin. The peak uptake in H460 tumors was 4.7% injected dose per gram at 15 min after injection, and the area under the curve (AUC 0-7 days ) was approximately one-half to one-third of the AUC 0-7 days in the kidneys, liver, and bone, where some toxicity is observed in humans. The radio-platinum tracer revealed the highly quantitative biodistribution of cisplatin, providing insights into the properties of cisplatin, including its adverse effects. The tracer enables a precise evaluation of pharmacokinetics for platinum-based drugs with high sensitivity.
Identifiants
pubmed: 36120823
doi: 10.1097/MNM.0000000000001614
pii: 00006231-202211000-00003
pmc: PMC9575570
doi:
Substances chimiques
Antineoplastic Agents
0
Platinum
49DFR088MY
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1121-1127Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 2016; 116:3436–3486.
Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ 2006; 83:728.
Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307–320.
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99:2467–2498.
Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67:1171–1176.
Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 2014; 6:2126–2133.
Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017; 22:609–619.
Hermann G, Heffeter P, Falta T, Berger W, Hann S, Koellensperger G. In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics 2013; 5:636–647.
Falta T, Koellensperger G, Standler A, Buchberger W, Maderc RM, Hann S. Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. J Anal At Spectrom 2009; 24:1336–1342.
Hennik MB, Vijgh WJF, Klein I, Elferink F, Vermorken JB, Winograd B, et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 1987; 47:6297–6301.
Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004; 57:756–763.
DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973; 33:1310–1315.
NuDat 3.0: a software product developed by National Nuclear Data Center (NNDC) at Brookhaven National Laboratory, http://www.nndc.bnl.gov/nudat2/index.jsp .
Obata H, Minegishi K, Nagatsu K, Ogawa M, Zhang MR. Synthesis of no-carrier-added [188, 189, 191Pt]cisplatin from a cyclotron produced 188, 189, 191PtCl42- complex. Sci Rep 2021; 11:8140.
Obata H, Tsuji AB, Sudo H, Sugyo A, Minegishi K, Nagatsu K, et al. In Vitro evaluation of no-carrier-added radiolabeled cisplatin ([189, 191Pt]cisplatin) emitting auger electrons. Int J Mol Sci 2021; 22:4622.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92–98.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363:733–742.
Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22:1329–1336.
Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986; 39:136–144.
Wang And X, Guo Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem 2007; 7:19–34.
Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ. Cisplatin binding sites on human albumin. J Biol Chem 1998; 273:14721–14730.
Zimmermann T, Zeizinger M, Burda JV. Cisplatin interaction with cysteine and methionine, a theoretical DFT study. J Inorg Biochem 2005; 99:2184–2196.
Wolf WC. Preparation and metabolism of a cisplatin/serum protein complex. Chem Biol Interact 1980; 30:223–235.
Holding JD, Lindup WE, van Laer C, Vreeburg GC, Schilling V, Wilson JA, Stell PM. Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. Br J Clin Pharmacol 1992; 33:75–81.
Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1993; 27:438–441.
Rashid NA, Halim SASA, Teoh SL, Budin SB, Hussan F, Ridzuan NRA, et al. The role of natural antioxidants in cisplatin-induced hepatotoxicity. Biomed Pharmacother 2021; 144:112328.
Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci 2006; 89:515–523.
Liu J, Liu Y, Habeebu SS, Klaassen CD. Metallothionein (MT)-null mice are sensitive to cisplatin-induced hepatotoxicity. Toxicol Appl Pharmacol 1998; 149:24–31.
Naziroglu M, Karaoğlu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195:221–230.
Christova TY, Gorneva GA, Taxirov SI, Duridanova DB, Setchenska MS. Effect of cisplatin and cobalt chloride on antioxidant enzymes in the livers of Lewis lung carcinoma-bearing mice: protective role of heme oxygenase. Toxicol Lett 2003; 138:235–242.
Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH 3) 2 Cl 2: distribution studies and dose calculations for 193m Pt and 195m Pt. J Nucl Med 1973; 14:191–195.
Lange RC, Spencer RP, Harder HC. Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum. II. J Nucl Med 1972; 13:328–330.
Areberg J, Björkman S, Einarsson L, Frankenberg B, Lundqvist H, Mattsson S, et al. Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin. Acta Oncol 1999; 38:221–228.
Smith HS, Taylor DM. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man. J Nucl Med 1974; 15:349–351.
Jordan NS, Schauer PK, Schauer A, Nightingale C, Golub G, Martin RS, Williams HM. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol 1985; 3:559–561.
Ludwig R, Alberts DS, Miller TP, Salmon SE. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 1984; 12:135–141.
Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 1973; 33:3091–3095.
Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14:104–107.
Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984; 53:837–840.
Posner MR, Ferrari L, Belliveau JF, Cummings FJ, Wiemann MC, O’Rourke A, et al. A phase I trial of continuous infusion cisplatin. Cancer 1987; 59:15–18.
Creagan ET, Richardson RL, Kovach JS. Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 1988; 6:1197–1201.